Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitapivat in sickle cell disease
NL-OMON54314Phase 2Recruiting
- Sponsor
- Agios Pharmaceuticals
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mitapivat in sickle cell disease (SCD) (7 arms), sponsored by Agios Pharmaceuticals. Primary endpoints: Hemoglobin response, Safety and 1 more. Started Nov 2023; status: recruiting.
02
Drugs
mitapivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NL-OMON54314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54314.